Salvage treatment in male patients with germ cell tumours

30Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

The outcome of salvage treatment was reviewed in 55 patients relapsing during or after their primary chemotherapy for advanced malignant germ cell tumours. Fifty-two patients had been given cisplatin-based chemotherapy as their primary treatment, whereas three patients had received carboplatin-based chemotherapy. The median time to relapse was 2 months (range: 0-96 months) from discontinuation of the primary treatment. Two patients underwent radical surgery only, and one patient had radiotherapy to a brain metastasis as his only curatively intended salvage treatment. Six patients did not receive any treatment for their recurrent malignancy (refusal, terminal condition) except for purely palliative measures. The disease-free survival for the total group was 27% at 5 years. Complete response to primary treatment lasting for ≥ 6 months was the only parameter which significantly predicted a favourable outcome (45% 5 year disease-free survival in 12 eligible patients). © 1993 Macmillan Press Ltd.

Cite

CITATION STYLE

APA

Josefsen, D., Ous, S., HøIe, J., Stenwig, A. E., & Fossa, S. D. (1993). Salvage treatment in male patients with germ cell tumours. British Journal of Cancer, 67(3), 568–572. https://doi.org/10.1038/bjc.1993.104

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free